DEFA14A: Keros Therapeutics Responds to Stockholder Pressure, Reaffirms Commitment to Maximizing Value

Keros Therapeutics addresses concerns raised by ADAR1 Capital Management, defends its board nominees, and highlights its ongoing strategic review process.

Summary

• Keros Therapeutics has issued a statement in response to ADAR1 Capital Management's public communications regarding the upcoming 2025 Annual Meeting of Stockholders.
• The company is currently undergoing a formal review process to evaluate strategic alternatives to maximize stockholder value, led by a Strategic Committee.
• Strategic alternatives under consideration include a potential sale of the company, business combination, continued investment in the pipeline, and/or return of excess capital to stockholders.
• ADAR1 has been pushing for an immediate return of capital to stockholders, and threatened to oppose the re-election of two directors if their nominee was not added to the board.
• Keros has a strong cash position and expects to fund its clinical programs and operations into 2029.
• A licensing agreement with Takeda Pharmaceuticals provides a $200 million upfront payment and potential milestones of up to $1.1 billion, along with tiered annual net sales royalties.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there's conflict with a shareholder, the company highlights its strong cash position and potential for future value creation through its pipeline and the Takeda partnership. The strategic review process introduces uncertainty but also the potential for positive outcomes.

Positives

• Keros has a proactive engagement program in place to ensure that stockholder perspectives are incorporated into the Board's decision-making process.
• The company has a strong cash position and expects to fund its clinical programs and operations into 2029.
• The exclusive license agreement with Takeda Pharmaceuticals provides a potential recurring capital source which could drive further value creation.

Negatives

• ADAR1's campaign threatens to distract focus from the Board's top priority of completing its review of strategic alternatives.
• There is no assurance that the review of strategic alternatives will result in the Company pursuing a transaction or any other strategic outcome.

Risks

• The strategic alternatives review process may not achieve its objectives.
• The review could have an adverse effect on the company's ability to retain and hire key personnel and maintain relationships with partners.
• The review could divert the attention and time of the company's management.
• There is a risk of unexpected costs or expenses resulting from the review.
• There is a risk of litigation relating to the review.
• Keros has a limited operating history and historical losses.
• Keros' ability to raise additional funding to complete the development and any commercialization of its product candidates is uncertain.
• Keros is dependent on the success of its product candidates, cibotercept, KER-065 and elritercept.
• Keros may be delayed in initiating, enrolling or completing any clinical trials.
• Keros faces competition from third parties that are developing products for similar uses.
• Keros' ability to obtain, maintain and protect its intellectual property is uncertain.
• Keros is dependent on third parties in connection with manufacturing, clinical trials and preclinical studies.

Future Outlook

Keros intends to provide a preliminary update regarding the status of the strategic review process within 60 days of its original announcement on April 10, 2025. Otherwise, Keros does not intend to disclose developments related to the process unless and until it determines that further disclosure is appropriate or necessary.

Management Comments

• The Board is committed to acting in the best interests of the Company and all of its stockholders.
• Keros values the views of its stockholders and has a proactive engagement program in place to ensure that their perspectives are incorporated into the Board's decision-making process.

Industry Context

This announcement reflects increasing shareholder activism in the biotech industry, where companies with promising pipelines but no current revenue are often targeted for strategic changes to unlock value. The pressure from ADAR1 is similar to other situations where hedge funds seek board representation or changes in capital allocation strategy.

Comparison to Industry Standards

• The $200 million upfront payment from Takeda is a significant deal for a clinical-stage biopharmaceutical company, comparable to similar licensing agreements in the industry.
• Companies like Arcus Biosciences and Relay Therapeutics have also entered into large partnerships with pharmaceutical companies, demonstrating the value of promising drug candidates.
• The strategic review process is a common response to shareholder pressure, with companies like Immunomedics previously exploring strategic alternatives before being acquired by Gilead.

Stakeholder Impact

• Shareholders: The strategic review process aims to maximize shareholder value, but there is no guarantee of a specific outcome.
• Employees: The strategic review process could impact job security depending on the outcome.
• Partners: The strategic review process could affect existing partnerships and future collaborations.

Next Steps

• The Strategic Committee will continue to evaluate strategic alternatives.
• Keros intends to provide a preliminary update regarding the status of the process within 60 days of its original announcement of the process on April 10, 2025.
• Stockholders will vote on the director nominees at the 2025 Annual Meeting on June 4, 2025.

Key Dates

Keywords

Keros Therapeutics, strategic alternatives, ADAR1 Capital Management, proxy statement, stockholder value, board of directors, clinical programs, Takeda Pharmaceuticals, director nominees, annual meeting